Effect of Treatment on Contagiousness of Patients with Active Pulmonary Tuberculosis

Infection Control and Hospital Epidemiology

Volumn 18, Issue 8, 1997, Pages 582-586

  Menzies, Dick ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

ANIMAL; CROSS INFECTION; DISEASE TRANSMISSION; DRUG EFFECT; HUMAN; ISOLATION AND PURIFICATION; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW;

ANIMALS; ANTITUBERCULAR AGENTS; CROSS INFECTION; HUMANS; MYCOBACTERIUM TUBERCULOSIS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; TUBERCULOSIS, PULMONARY;

EID: 0031205131     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.2307/30141272     Document Type: Review

References (54)

1. Fischl MA. Nosocomial transmission of multi-drug resistant tuberculosis among HIV-infected persons - Florida and New York, 1988-1991. MMWR 1991;40:585-591.
2. Coronado V, Beck-Sague C, Hutton M, et al. Transmission of multi-drug resistant Mycobacterium tuberculosis among persons with human immunodeficiency virus infection in an urban hospital: epidemiologic and restriction fragment polymorphism analysis. J Infect Dis 1993;168:1052-1055.
3. Pearson ML, Jereb JA, Frieden TR, Crawford JT. Nosocomial transmission of multi-drug resistant Mycobacterium tuberculosis: a risk to patients and healthcare workers. Ann Intern Med 1992;117:191-196.
4. Beck-Sague C, Dooley SW, Hutton MD, et al. Hospital outbreak of multi-drug resistant Mycobacterium tuberculosis infections: factors in transmission to staff and HIV-infected patients. JAMA 1992;268:1280-1286.
5. Edlin BR, Tokars JI, Grieco MH, et al. An outbreak of multi-drug resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;326:1514-1521.
6. Centers for Disease Control. Guidelines for preventing the transmission of tuberculosis in health-care settings, with special focus on HIV-related issues. MMWR 1990;39:1-29.
7. American Thoracic Society. Control of tuberculosis in the United States. Am Rev Respir Dis 1992;146:1623-1633.
8. Centers for Disease Control and Prevention. Draft guidelines for preventing the transmission of tuberculosis in health care facilities. 2nd ed. Federal Register 1993;58:52810-52854.
9. Centers for Disease Control and Prevention. Recommendations and reports. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities. MMWR 1994;43:13.
10. Menzies RI, Fanning A, Yuan L, Fitzgerald JM. Tuberculosis among health care workers. N Engl J Med 1995;332:92-98.
11. Jarvis WR, Bolyard EA, Bozzi CJ, et al. Respirators, recommendations, and regulations: the controversy surrounding protection of health care workers from tuberculosis. Ann Intern Med 1995;122:142-146.
12. Iseman MD. A leap of faith: what can we do to curtail intrainstitutional transmission of tuberculosis? Ann Intern Med 1992;117:251-253.
13. Leff A, Geppert EF. Public health and preventive aspects of pulmonary tuberculosis. Arch Intern Med 1979;139:1405-1410.
14. Rouillon A, Perdrizet S, Parrot R. Transmission of tubercle bacilli: the effects of chemotherapy. Tubercle 1976;57:275-299.
15. American Thoracic Society. Bacteriologic standards for the discharge of patients. Am Rev Respir Dis 1974;102:470-473.
16. Menzies RI. Tuberculosis control in hospitals. In: Fitzgerald JM, ed. Canadian Tuberculosis Standards. Ottawa, Ontario, Canada: Canadian Lung Association; 1995.
17. Health Canada. Guidelines for preventing the transmission of tuberculosis in Canadian health care facilities and other institutional settings. Ottawa, Ontario, Canada: Government of Canada; 1996.
18. Wells WF. Airborne Contagion and Air Hygiene: An Ecological Study of Droplet Infections. Cambridge, MA: Harvard University Press; 1955
19. Rose CE, Zerbe GO, Lantz SO, Bailey WC. Establishing priority during investigation of tuberculosis contacts. Am Rev Respir Dis 1979;119:603-609.
20. Riley RL, Nardell EA. Clearing the air: the theory and application of ultraviolet air disinfection. Am Rev Respir Dis 1989;139:1286-1294.
21. Riley RL. Airborne infection: strategies for interrupting transmission. Bull Int Union Tuberc Lung Dis 1991;66:55-56.
22. Toman K. Tuberculosis - Case-Finding and Chemotherapy: Questions and Answers. Geneva, Switzerland: World Health Organization; 1979.
23. Loudon RG, Spohn SK. Cough frequency and infectivity in patients with pulmonary tuberculosis. Am Rev Respir Dis 1969;99:109-111.
24. Hertzberg G. The infectiousness of human tuberculosis. Acta Tuberc Scand 1957;38(suppl):1-146.
25. Van Geuns HA, Meijer J, Styblo K. Results of contact examination in Rotterdam, 1967-1969. Bull Int Union Tuberc 1975;50:107-121.
26. Grzybowski S, Barnett GD, Styblo K. Contacts of cases of active pulmonary tuberculosis. Bull IUAT 1975;50:90-106.
27. Capewell S, Leitch AG. The value of contact procedures for tuberculosis in Edinburgh. Br J Dis Chest 1984;78:317-328.
28. Riley RL, Mills CC, O'Grady FO, Sultan LU, Wittstadt F, Shivpuri DN. Infectiousness of air from a tuberculosis ward: ultraviolet irradiation of infected air - comparative infectiousness of different patients. Am Rev Respir Dis 1962;85:511-525.
29. Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bacterial activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980;121:939-949.
30. Singapore Tuberculosis Service, British Medical Research Council. Controlled trial of intermittent regimens of rifampicin plus isoniazid for pulmonary tuberculosis in Singapore. Lancet 1975;7945:1105-1109.
31. East African, British Medical Research Council. Controlled clinical trial of short-course (6 month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1972;7760:1079-1085.
32. Tousek J, Votruba R. Rifampicin plus isoniazid, rifampicin plus PAS, and isoniazid plus PAS in the initial treatment of pulmonary tuberculosis. Chemotherapy 1974;20:183-200.
33. Tuberculosis Research Center. Study of chemotherapy regimens of 5 and 7 months' duration and the role of corticosteroids in the treatment of sputum-positive patients with pulmonary tuberculosis in South India. Tubercle 1983;64:73-91.
34. Kim TC, Blackman RS, Heatwole KM, Kim T, Rochester DF. Acid-fast bacilli in sputum smears of patients with pulmonary tuberculosis. Am Rev Respir Dis 1984;129:264-268.
35. Clancy LJ, Kelly P, O'Reilly L, Byrne C, Costello E. The pathogenicity of Mycobacterium tuberculosis during chemotherapy. Eur Respir J 1990;3:399-402.
36. Loudon RG, Bumgarner LR, Coffman GK. Isoniazid and the survival of tubercule bacilli in airborne droplet nuclei. Am Rev Respir Dis 1969;100:172-176.
37. Haley CE, McDonald RC, Rossi L, Jones WD, Haley RW, Luby JP. Tuberculosis epidemic among hospital personnel. Infect Control Hosp Epidemiol 1989;10:204-210.
38. Kamat SR, Dawson JJY, Devadatta S, et al. A controlled study of the influence of segregation of tuberculous patients for one year on the attack rate of tuberculosis in a 5-year period in close family contacts in South India. Bull World Health Organ 1966;34:517-532.
39. Gunnels JJ, Bates JH, Swindoll H. Infectivity of sputum-positive patients on chemotherapy. Am Rev Respir Dis 1974;109:323-330.
40. Riley RL, Moodie AS. Infectivity of patients with pulmonary tuberculosis in inner-city homes. Am Rev Respir Dis 1974;110:810-812.
41. Brooks SM, Lassiter NL, Young EC. A pilot study concerning the infection risk of sputum positive tuberculous patients on chemotherapy. Am Rev Respir Dis 1973;108:799-803.
42. Abeles H. Early hospital discharge of tuberculous patients with sputum containing acid-fast bacilli on microscopic examination. Am Rev Respir Dis 1973;108:975-977.
43. Snider DE, Kelly GD, Cauthen GM, Thompson NJ, Kilburn JO. Infection and disease among contacts of tuberculosis cases with drug-resistant and drug-susceptible bacilli. Am Rev Respir Dis 1985;132:125-132.
44. Aitken ML, Anderson KM, Albert RK. Is the tuberculosis screening program of hospital employees still required? Am Rev Respir Dis 1987;136:805-807.
45. Vogeler DM, Burke JP. Tuberculosis screening for hospital employees: a five-year experience in a large community hospital. Am Rev Respir Dis 1978;117:227-232.
46. Raad I, Cusick J, Sherertz RJ, Sabbagh M, Howell N. Annual tuberculin skin testing of employees at a university hospital: a cost-benefit analysis. Infect Control Hosp Epidemiol 1989;10:465-468.
47. Adal KA, Anglim AM, Palumbo CL, Titus MG, Coyner BJ, Farr BM. Preventing nosocomial tuberculosis with HEPA respirators: a cost-effectiveness analysis. N Engl J Med 1994;331:169-173.
48. Menzies RI, Vissandjee B, Rocher I, St. Germain Y. The booster effect in two-step tuberculin testing among young adults in Montreal. Ann Intern Med 1994;120:190-198.
49. Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. N Engl J Med 1992;326:231-235.
50. Fischl MA, Daikos GL, Uttamchandani RB, et al. Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug resistant bacilli. Ann Intern Med 1992;117:184-190.
51. Fischl MA, Uttamchandani RB, Daikos GL, et al. An outbreak of tuberculosis caused by multiple-drug resistant tubercle bacilli among patients with HIV infection. Ann Intern Med 1992;117:177-183.
52. Alland D, Kalkut GE, Moss AR, et al. Transmission of tuberculosis in New York City: an analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med 1994;330:1710-1716.
53. Small PM, Hopewell PC, Singh SP, et al. The epidemiology of tuberculosis in San Francisco: a population-based study using conventional and molecular methods. N Engl J Med 1994;330:1703-1709.
54. Genewein A, Telenti A, Bernasconi C, et al. Molecular approach to identifying route of transmission of tuberculosis in the community. Lancet 1993;342:841-844.